![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 5
Zeitschriftenartikel
Möbus, V.; Jackisch, C.; Luck, H. J.; du Bois, A.; Thomssen, C.; Kuhn, W.; Nitz, U.; Schneeweiss, A.; Huober, J.; Harbeck, N.; Minckwitz, G. von; Runnebaum, I. B.; Hinke, A.; Konecny, G. E.; Untch, M. und Kurbacher, C.
(2018):
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.
In: Annals of Oncology, Bd. 29, Nr. 1: S. 178-185
Nitz, U.; Gluz, O.; Huober, J.; Kreipe, H. H.; Kates, R. E.; Hartmann, A.; Erber, R.; Moustafa, Z.; Scholz, M.; Lisboa, B.; Mohrmann, S.; Möbus, V.; Augustin, D.; Hoffmann, G.; Weiss, E.; Böhmer, S.; Kreienberg, R.; Bois, A. du; Sattler, D.; Thomssen, C.; Kiechle, M.; Jänicke, F.; Wallwiener, D.; Harbeck, N. und Kuhn, W.
(2017):
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression (vol 25, pg 1551, 2014).
In: Annals of Oncology, Bd. 28, Nr. 11: S. 2899
Elger, T.; Decker, T.; Fehm, T.; Fuxius, S.; Harbeck, N.; Juhasz-Böss, I.; Möbus, V.; Thomssen, C.; Seehase, M.; Schollenberger, L.; Ruckes, C. und Schmidt, M.
(2017):
VinoMetro: Phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR plus )/human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy.
In: Annals of Oncology, Bd. 28
Krajnak, S.; Decker, T.; Fehm, T.; Fuxius, S.; Harbeck, N.; Juhasz-Böss, I.; Möbus, V.; Thomssen, C.; Seehase, M.; Schollenberger, L.; Ruckes, C. und Schmidt, M.
(2017):
VinoMetro: phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2-breast cancer resistant to endocrine therapy.
In: Oncology Research and Treatment, Bd. 40: S. 88
Gluz, O.; Liedtke, C.; Huober, J.; Peyro-Saint-Paul, H.; Kates, R. E.; Kreipe, H. H.; Hartmann, A.; Pelz, E.; Erber, R.; Mohrmann, S.; Möbus, V.; Augustin, D.; Hoffmann, G.; Thomssen, C.; Jänicke, F.; Kiechle, M.; Wallwiener, D.; Kuhn, W.; Nitz, U. und Harbeck, N.
(2016):
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2-early breast cancer: WSG-AGO EC-Doc Trial.
In: Annals of Oncology, Bd. 27, Nr. 6: S. 1035-1040